Adlai Nortye Ltd. (NASDAQ:ANL – Free Report) – Research analysts at Cantor Fitzgerald raised their FY2024 EPS estimates for shares of Adlai Nortye in a note issued to investors on Tuesday, April 23rd. Cantor Fitzgerald analyst L. Chen now anticipates that the company will post earnings per share of ($2.41) for the year, up from their prior forecast of ($2.50). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Adlai Nortye’s current full-year earnings is ($2.90) per share.
Adlai Nortye Price Performance
Shares of NASDAQ ANL opened at $13.75 on Thursday. The business has a 50 day simple moving average of $9.45 and a 200 day simple moving average of $9.33. Adlai Nortye has a 52 week low of $7.11 and a 52 week high of $19.30.
Institutional Investors Weigh In On Adlai Nortye
About Adlai Nortye
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.
Further Reading
- Five stocks we like better than Adlai Nortye
- Financial Services Stocks Investing
- 3 Stocks Leading the U.S. Agriculture Comeback
- Best Stocks Under $5.00
- How to Use Put Debit Spreads to Profit From Falling Stocks
- The “How” and “Why” of Investing in 5G Stocks
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Adlai Nortye Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adlai Nortye and related companies with MarketBeat.com's FREE daily email newsletter.